It leads the development of CAR treatments with a new concept of an anti-cancer immunotherapy platform for various refractory
carcinomas.

Starting with the world's first anti-cancer immunotherapeutics for pet dogs, Vaxleukin-15, We are moving to the world's first and best with the more efficient Vaxleukin-15 ver2.0, and the development of exclusive treatments for other pets.